Your browser doesn't support javascript.
loading
Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from the EUROAPS registry.
Alijotas-Reig, Jaume; Esteve-Valverde, Enrique; Ferrer-Oliveras, Raquel; Sáez-Comet, Luis; Lefkou, Elmina; Mekinian, Arsène; Belizna, Cristina; Ruffatti, Amelia; Hoxha, Ariela; Tincani, Angela; Nalli, Cecilia; Marozio, Luca; Maina, Aldo; Espinosa, Gerard; Ríos-Garcés, Roberto; Cervera, Ricard; Carolis, Sara De; Monteleone, Giuseppina; Latino, Omar; Udry, Sebastian; LLurba, Elisa; Garrido-Gimenez, Carmen; Trespidi, Laura; Gerosa, Maria; Chighizola, Cecilia Beatrice; Rovere-Querini, Patrizia; Canti, Valentina; Mayer-Pickel, Karoline; Tabacco, Sara; Arnau, Anna; Trapé, Jaume; Ruiz-Hidalgo, Domingo; Sos, Laia; Farran-Codina, Inmaculada.
Afiliação
  • Alijotas-Reig J; Systemic Autoimmune Disease Unit, Department of Internal Medicine, Vall d'Hebron University Hospital, Barcelona.
  • Esteve-Valverde E; Department of Medicine, Universitat Autònoma, Barcelona.
  • Ferrer-Oliveras R; Internal Medicine Department, Althaia Healthcare University Network of Manresa, Systemic Autoimmune Disease Unit, Manresa, Barcelona.
  • Sáez-Comet L; Obstetrics and Gynaecology Department. Hospital Quirón, Barcelona.
  • Lefkou E; Internal Medicine Department, Miguel Servet University Hospital, Zaragoza, Spain.
  • Mekinian A; Haematology Unit, Hippokration Hospital of Thessaloniki, Thessaloniki, Greece.
  • Belizna C; AP-HP, Hôpital Saint-Antoine, Service de médecine interne and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Sorbonne Universités, UPMC Univ, Paris.
  • Ruffatti A; Vascular and Coagulation Department, University Hospital Angers and CNRS, 6015 INSERM 1083 Unit, Angers, France.
  • Hoxha A; Rheumatology Unit, Department of Medicine-DIMED, University of Padua, Padua.
  • Tincani A; Rheumatology Unit, Department of Medicine-DIMED, University of Padua, Padua.
  • Nalli C; Rheumatology and Clinical Immunology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia.
  • Marozio L; Rheumatology and Clinical Immunology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia.
  • Maina A; Department of Obstetrics and Gynaecology, Università di Torino, Torino.
  • Espinosa G; Department of Internal Medicine, AO Città della Salute e della Scienza di Torino, Turin, Italy.
  • Ríos-Garcés R; Department of Autoimmune Diseases, Hospital Clinic, Institut de Recerca Biomèdica August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
  • Cervera R; Department of Autoimmune Diseases, Hospital Clinic, Institut de Recerca Biomèdica August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
  • Carolis S; Department of Autoimmune Diseases, Hospital Clinic, Institut de Recerca Biomèdica August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
  • Monteleone G; UOC di Patologia Ostetrica, Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome.
  • Latino O; Istituto di Clinica Ostetrica e Ginecologica, Universita Cattolica del Sacro Cuore, Rome, Italy.
  • Udry S; UOC di Patologia Ostetrica, Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome.
  • LLurba E; Autoimmune, Thrombophilic Diseases and Pregnancy Division, Dr Carlos G. Durand Hospital, Buenos Aires, Argentina.
  • Garrido-Gimenez C; Autoimmune, Thrombophilic Diseases and Pregnancy Division, Dr Carlos G. Durand Hospital, Buenos Aires, Argentina.
  • Trespidi L; Obstetrics and Gynaecology Department, High Risk Unit, University Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Gerosa M; Obstetrics and Gynaecology Department, High Risk Unit, University Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Chighizola CB; Obstetrics and Gynaecology Department, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan.
  • Rovere-Querini P; Division of Rheumatology, Department of Clinical Sciences and Community Health, University of Milan, Milan.
  • Canti V; Division of Rheumatology, Department of Clinical Sciences and Community Health, University of Milan, Milan.
  • Mayer-Pickel K; Pregnancy and Rheumatic Diseases Clinic Unit of Medicine and Clinical Immunology IRCCS Ospedale San Raffaele Università Vita-Salute San Raffaele, Milan.
  • Tabacco S; Pregnancy and Rheumatic Diseases Clinic Unit of Medicine and Clinical Immunology IRCCS Ospedale San Raffaele Università Vita-Salute San Raffaele, Milan.
  • Arnau A; Department of Obstetrics, Medical University Graz, Graz, Austria.
  • Trapé J; Department of Gynecology Obstetrics and Urology, "Sapienza" University of Rome, Rome, Italy.
  • Ruiz-Hidalgo D; Clinical Research Unit, Althaia Healthcare University Network of Manresa, University of Vic - Central University of Catalonia, Barcelona.
  • Sos L; Department of Laboratory Medicine, Althaia Healthcare University Network of Manresa, University of Vic - Central University of Catalonia, Barcelona.
  • Farran-Codina I; Internal Medicine Department, Althaia Healthcare Network of Manresa, Manresa, University of Vic - Central University of Catalonia, Barcelona.
Rheumatology (Oxford) ; 59(6): 1306-1314, 2020 06 01.
Article em En | MEDLINE | ID: mdl-31580459
ABSTRACT

OBJECTIVES:

To compare clinical features, laboratory data and fetal-maternal outcomes between 1000 women with obstetric APS (OAPS) and 640 with aPL-related obstetric complications not fulfilling Sydney criteria (non-criteria OAPS, NC-OAPS).

METHODS:

This was a retrospective and prospective multicentre study from the European Registry on Obstetric Antiphospholipid Syndrome.

RESULTS:

A total of 1650 women with 5251 episodes, 3601 of which were historical and 1650 latest episodes, were included. Altogether, 1000 cases (OAPS group) fulfilled the Sydney classification criteria and 650 (NC-OAPS group) did not. Ten NC-OAPS cases were excluded for presenting thrombosis during follow-up. All cases were classified as category I (triple positivity or double positivity for aPL) or category II (simple positivity). Overall, aPL laboratory categories showed significant differences 29.20% in OAPS vs 17.96% in NC-OAPS (P < 0.0001) for category I, and 70.8% in OAPS vs 82% in NC-OAPS (P < 0.0001) for category II. Significant differences were observed when current obstetric complications were compared (P < 0.001). However, major differences between groups were not observed in treatment rates, livebirths and thrombotic complications. In the NC-OAPS group, 176/640 (27.5%) did not fulfil Sydney clinical criteria (subgroup A), 175/640 (27.34%) had a low titre and/or non-persistent aPL positivity but did meet the clinical criteria (subgroup B) and 289/640 (45.15%) had a high aPL titre but did not fulfil Sydney clinical criteria (subgroup C).

CONCLUSION:

Significant clinical and laboratory differences were found between groups. Fetal-maternal outcomes were similar in both groups when treated. These results suggest that we could improve our clinical practice with better understanding of NC-OAPS patients.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Complicações na Gravidez / Aspirina / Síndrome Antifosfolipídica Tipo de estudo: Observational_studies Limite: Adult / Female / Humans / Pregnancy Idioma: En Revista: Rheumatology (Oxford) Assunto da revista: REUMATOLOGIA Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Complicações na Gravidez / Aspirina / Síndrome Antifosfolipídica Tipo de estudo: Observational_studies Limite: Adult / Female / Humans / Pregnancy Idioma: En Revista: Rheumatology (Oxford) Assunto da revista: REUMATOLOGIA Ano de publicação: 2020 Tipo de documento: Article